Fort Worth, TX, United States of America

Galderma Laboratories Inc.


USPTO Granted Patents = 27

% Expired Patents = 48.1


Trademarks = 9

Forward Citations = 245

Loading Chart...
Loading Chart...

21 inventors (with patents filed for the assignee):

goldMedal Jack A DeJovin (12 out of 12 patents)

silverMedal Isabelle Jean DeJovin (10 out of 10 patents)

bronzeMedal Robert A Ashley (7 out of 17 patents)

4.  Michael Graeber (6 out of 30 patents)

5.  Philip Freidenreich (6 out of 7 patents)

6.  Matthew James Leoni (6 out of 10 patents)

7.  Christian Loesche (6 out of 12 patents)

8.  Yin-sang Liu (4 out of 4 patents)

9.  Yin-Sang Liu (2 out of 2 patents)

10.  Philippe Andres (1 out of 13 patents)

11.  Jean-Christophe Buge (1 out of 11 patents)

12.  André Jomard (1 out of 8 patents)

13.  Arthur Clapp (1 out of 3 patents)

14.  Christopher Powala (1 out of 9 patents)

15.  Karine Nadau Fourcade (1 out of 2 patents)


Core Competencies:
Brimonidine
Acne Treatment
Erythema
Psoriasis
Inflammatory Skin Disorders
Combination Therapy
Facial Flushing
Telangiectasis
Skin Wrinkles
Rosacea
Thrombin Inhibition

27 patents:

Galderma Laboratories Inc. is a global leader in dermatology, dedicated to advancing skin health through innovative products and solutions. The company specializes in developing and manufacturing a wide range of medical and aesthetic dermatological treatments, including prescription medications, over-the-counter products, and cosmetic injectables. With a strong focus on research and development, Galderma aims to address various skin conditions and enhance the quality of life for patients worldwide, operating from its headquarters in Fort Worth, Texas.
Profile summary based on public USPTO records.

logo

Company Badge

USPTO Data Jan 1 1976 - Sep 29 2026

Galderma Laboratories Inc.
27 Patents

#36 in Fort Worth, TX

#710 in Texas

#12,405 in US

#23,968 in the World

Fort Worth, TX (US)
Fort Worth, TX, United States of America
Forward Citations = 245

21 inventors:

Please report any incorrect information to [email protected]
Loading…